INTRODUCTION {#s1}
============

Prognostic assessment of hepatocellular carcinoma (HCC) is very important for clinicians and patients. The relevant knowledge is being rapidly accumulated. Traditional prognostic variables mainly include portal vein thrombosis, tumor size, and alpha-fetoprotein, etc. \[[@R1]\]. As for the prognostic staging of HCC, the Barcelona Clinic Liver Cancer (BCLC) system is the most frequently used tool with 5 major parameters, such as tumor size, tumor number, Child-Pugh class, physical status, and tumor metastasis \[[@R2]\]. Several alternative staging systems include the Cancer of the Liver Italian Program (CLIP) system \[[@R3]\], the Hong Kong Liver Cancer (HKLC) system \[[@R4]\], and the Japan Integrated Scoring (JIS) system \[[@R5]\]. As for the liver function assessment of HCC, Child-Pugh class is the most frequently used tool with 5 variables, such as bilirubin, albumin, international normalized ratio, ascites, and hepatic encephalopathy \[[@R6]\]. Albumin-bilirubin score is a recently developed and more convenient tool \[[@R7]\]. More recently, the associations of inflammation-based markers with the prognosis of HCC have been actively explored. Neutrophil to lymphocyte ratio (NLR), which refers to the ratio of neutrophil to lymphocyte count, is a readily available marker for assessing the systemic inflammatory changes. NLR reflects the potential balance between neutrophil-associated pro-tumor inflammation and lymphocyte-dependent anti-tumor immune function \[[@R8]--[@R11]\]. An elevated NLR may represent a trend towards increased pro-tumor inflammation and decreased anti-tumor immune function. Herein, we have conducted a systematic review and meta-analysis to analyze the prognostic role of NLR in HCC patients treated with different treatment options. This work was registered at PROSPERO database (registration number: CRD CRD42016033409).

RESULTS {#s2}
=======

Study selection and characteristics {#s2_1}
-----------------------------------

A total of 598 papers were identified. Among them, 90 papers with 20,475 HCC patients were included in the systematic review (Figure [1](#F1){ref-type="fig"}) \[[@R12]--[@R101]\]. Study characteristics were summarized in Table [1](#T1){ref-type="table"}. According to the publication type, 21 and 69 papers were published in abstract and full-text forms, respectively. According to the study design, 60 and 5 papers were retrospective and prospective, respectively; 2 papers were both retrospective and prospective; and the study design was not available in 23 papers. According to the regions, 63, 14, and 13 studies were conducted by Asian, European, and American researchers, respectively.

![Flowchart of study inclusion](oncotarget-07-45283-g001){#F1}

###### Study characteristics

  First author       Journal (Year)                                                 Type of publication   Study design                 Regions                        Enrollment period         Study population                                                                               No. Pts
  ------------------ -------------------------------------------------------------- --------------------- ---------------------------- ------------------------------ ------------------------- ---------------------------------------------------------------------------------------------- ---------
  Abdelmessih RM     Hepatology (2011)                                              Abstract              Retrospective                NY, US                         1999.3-- 2010.4           HCC patients who were downstaged with TACE prior to LT                                         200
  Afshar M           Journal of Hepatology (2015)                                   Abstract              Retrospective                Birmingham, UK                 2009.4-- 2014.3           HCC patients treated with sorafenib                                                            217
  Agopian VG         Journal of the American College of Surgeons (2015)             Full-text             Retrospective                CA, US                         1984-- 2013               HCC patients treated with LT                                                                   865
  Aino H             Molecular and Clinical Oncology (2014)                         Full-text             NA                           Fukuoka, Japan                 1998.4-- 2012.4           Advanced HCC patients with extrahepatic metastasis                                             419
  Bertuzzo VR        Transplantation (2011)                                         Full-text             Retrospective                Bologna, Italy                 1997-- 2009               HCC patients treated with LT                                                                   219
  Bodzin A           American Journal of Transplantation (2015)                     Abstract              Retrospective                CA, US                         1984-- 2014               Recurrent HCC after LT                                                                         106
  Bronson N          HPB (2012)                                                     Abstract              Retrospective                PA, US                         2002.6-- 2011.7           HCC patients treated with resection                                                            68
  Bruixola G         Journal of Clinical Oncology (2015)                            Abstract              Retrospective                Valencia, Spain                2008-- 2014               HCC patients treated with sorafenib                                                            145
  Chan AW            Annals of Surgical Oncology (2011)                             Full-text             Retrospective                Hong Kong, China               2001.1-- 2011.12          BCLC stage 0/A primary HCC patients treated with surgical resection                            597
  Chang JX           Annals of Oncology (2014)                                      Abstract              Retrospective                Beijing, China                 2008-- 2009               Advanced HCC patients treated with cryoablation                                                150
  Chen TM            Journal of Gastroenterology and Hepatology (2012)              Full-text             Retrospective                Taiwan, China                  2003.7-- 2010.12          Early HCC patients treated with RFA                                                            158
  Chen X             British Journal of Surgery (2012)                              Full-text             Prospective                  Hong Kong, China               2009.4-- 2011.5           HCC patients with Child-Pugh grade A who underwent partial hepatectomy                         190
  Chen Z             Supportive Care in Cancer (2014)                               Abstract              NA                           Guangzhou, China               2008.9-- 2010.6           Advanced HCC patients without fever or signs of infection                                      219
  da Fonseca LG      Medical Oncology (2014)                                        Full-text             Retrospective                Sao Paulo, Brazil              2009.7-- 2013.11          HCC patients who received sorafenib as initial systemic treatment                              120
  Dan J              PLoS ONE (2013)                                                Full-text             Retrospective                Guangzhou, China               2005.5-- 2008.8           Small HCC patients treated with RFA                                                            178
  Facciorusso A      Journal of Gastroenterology and Hepatology (2014)              Full-text             NA                           Foggia, Italy                  2005.4-- 2010.2           HCC patients treated with RFA                                                                  103
  Fan W              PLoS ONE (2015)                                                Full-text             Retrospective                Guangzhou, China               2003.1-- 2012.12          Recurrent HCC patients treated with TACE                                                       132
  Fu SJ              Medical Oncology (2013)                                        Full-text             NA                           Guangzhou, China               2006.1-- 2009.4           HBV-associated HCC patients treated with radical hepatectomy                                   282
  Fu YP              Liver Cancer (2015)                                            Abstract              NA                           Guangzhou, China               NA                        HCC patients treated with curative resection                                                   772
  Gao F              Medicine (2015)                                                Full-text             Retrospective                Beijing, China                 2008.10-- 2012.5          Newly diagnosed with HCC                                                                       825
  Gomez D; Farid S   World Journal of Surgery (2008); HPB (2010, Abstract)          Full-text             NA                           Leeds, UK                      1994.1-- 2007.4           HCC patients treated with curative resection                                                   96
  Guo ZX             Chinese Journal of Cancer (2009)                               Full-text             Retrospective                Guangzhou, China               2000-- 2005               HCC patients treated with curative resection (age \<35 years old)                              91
  Halazun KJ         Annals of Surgery (2009)                                       Full-text             Retrospective                NY, US                         2001-- 2007               HCC patients treated with LT                                                                   150
  Harimoto N         Transplantation (2013)                                         Full-text             Retrospective                Fukuoka, Japan                 1996.10-- 2012.8          HCC patients treated with LDLT                                                                 167
  Higashi T          Annals of Surgical Oncology (2015)                             Full-text             Prospective                  Kumamoto, Japan                2008-- 2012               HCC patients treated with resection                                                            215
  Hu B               Clinical Cancer Research (2014)                                Full-text             Retrospective/Prospective    Shanghai, China                2005-- 2006/2010-- 2011   HCC patients treated with curative resection                                                   133/123
  Huang GQ           Oncotarget (2015)                                              Full-text             Retrospective                Wenzhou, China                 2007.1-- 2014.1           HCC patients treated with curative resection                                                   508
  Huang J            Medical Oncology (2014)                                        Full-text             Prospective                  Guangzhou, China               2008-- 2009               HCC patients treated with hepatectomy as initial treatment                                     349
  Huang ZL           Journal of Vascular and Interventional Radiology (2011)        Full-text             Retrospective                Guangzhou, China               2001-- 2004               HCC patients treated with TACE                                                                 145
  Kanno Y            Clinical Nutrition (2014)                                      Abstract              NA                           Mibu, Japan                    2000-- 2012               HCC patients treated with curative surgery                                                     418
  Kim DG             Hepatology (2013)                                              Abstract              NA                           Seoul, South Korea             2000.10-- 2011.11         HCC patients treated with LDLT                                                                 224
  Kinoshita A        Annals of Surgical Oncology (2015)                             Full-text             Prospective; Retrospective   Tokyo, Japan                   2005.1-- 2012.8           Newly diagnosed HCC                                                                            186
  Lai Q              Transplantation International (2014)                           Full-text             NA                           Brussels, Belgium              1994.1-- 2012.3           Patients with pre-LT proven diagnosis of HCC who entered the waiting list for LT               181
  Li C               Journal of Surgical Research (2015)                            Full-text             NA                           Chengdu, China                 2007-- 2014               HBV-associated HCC patients treated with resection                                             236
  Li JP              Chinese Journal of Cancer Prevention and Treatment (2013)      Full-text             Retrospective                Jinan, China                   2006.2-- 2009.2           Unresectable HCC patients treated with TACE                                                    154
  Li X               Tumor Biology (2014)                                           Full-text             Retrospective                Guangzhou, China               2008.11-- 2010.4          Advanced HCC patients (BCLC stages C and D) who did not receive sorafenib                      205
  Li X               PLoS ONE (2014)                                                Full-text             Retrospective                Beijing, China                 2006.4-- 2014.4           Recurrent HCC patients treated with curative thermal ablation                                  506
  Liao R             World Journal of Surgical Oncology (2015)                      Full-text             Retrospective                Chongqing, China               2007.1-- 2010.12          Single-nodule small HCC patients treated with curative resection                               222
  Liao W             Translational Oncology (2014)                                  Full-text             Retrospective                Guilin, China                  1999.9-- 2007.6           HCC patients treated with curative resection                                                   256
  Liese J            Transplantation (2014)                                         Abstract              Retrospective                Frankfurt, Germany             2007.1-- 2012.12          HCC patients treated with LT                                                                   92
  Limaye AR          Hepatology Research (2013)                                     Full-text             Retrospective                FL, US                         2000-- 2008               HCC patients treated with LT                                                                   160
  Long J             Hepatology International (2016)                                Full-text             Prospective                  Beijing, China                 2010.8-- 2014.7           HCC with PVTT patients treated with microwave ablation after TACE                              60
  Lu D               Transplantation (2015)                                         Abstract              NA                           Hangzhou, China                2002-- 2012               Small HCC patients treated with LT                                                             140
  Luè A              Journal of Hepatology (2014)                                   Abstract              NA                           4 different hospitals, Spain   2005.8-- 2013.10          HCC patients treated with sorafenib                                                            186
  Mano Y             Annals of Surgery (2013)                                       Full-text             Retrospective                3 different hospitals, Japan   1996.1-- 20009.12         HCC patients treated with curative resection                                                   958
  McNally ME         Annals of Surgical Oncology (2013)                             Full-text             Retrospective                OH, US                         A 10--year period         HCC patients treated with TACE                                                                 104
  Mizukoshi E        Hepatology (2015)                                              Abstract              NA                           Kanazawa, Japan                NA                        HCC patients treated with hepatic arterial infusion chemotherapy                               36
  Motomura T         Journal of Hepatology (2013)                                   Abstract              NA                           Fukuoka, Japan                 1999.7-- 2011.3           HCC patients treated with LT                                                                   158
  Na GH              World Journal of Gastroenterology (2014)                       Full-text             Retrospective                Seoul, South Korea             2000.10-- 2011.11         HCC patients treated with LDLT                                                                 224
  Nagai S            Transplantation (2015)                                         Abstract              NA                           IN, US                         2001-- 2012               HCC patients treated with LT                                                                   268
  Ni XC              Medicine (2015)                                                Full-text             Retrospective                Shanghai, China                2010.12-- 2012.1          HCC patients treated with resection (test cohort)                                              367
  Oh BS              BMC Cancer (2013)                                              Full-text             Retrospective                Seoul, South Korea             2007.1-- 2010.12          Newly diagnosed HCC                                                                            318
  Okamura Y          World Journal of Surgery (2015)                                Full-text             Retrospective                Shizuoka, Japan                2002.9-- 2012.11          HCC patients treated with resection                                                            256
  Parisi I           Liver Transplantation (2014)                                   Full-text             NA                           London, UK                     1996-- 2010               HCC patients treated with LT                                                                   150
  Peng W             Journal of Surgical Research (2014)                            Full-text             Retrospective                Chengdu, China                 2007.2-- 2012.3           Small HCC patients treated with curative resection                                             189
  Pinato DJ          Translational Research (2012)                                  Full-text             Retrospective                London, UK                     NA                        HCC patients treated with TACE                                                                 54
  Pinato DJ          Journal of Hepatology (2012)                                   Full-text             Retrospective                London, UK                     1993-- 2011               HCC patients (training set)                                                                    112
  Ruan DY            World Journal of Gastroenterology (2015)                       Full-text             Retrospective                Guangzhou, China               2003.9-- 2011.6           HCC patients treated with curative resection                                                   200
  Shindoh J          Transplant International (2014)                                Full-text             Retrospective                Tokyo, Japan                   1996.1-- 2012.12          HCC patients treated with LDLT                                                                 124
  Sirin G            Hepatology International (2015)                                Abstract              Retrospective                Kocaeli, Japan                 2007-- mid--2012          HCC patients treated with segmental resection and/or RFA                                       49
  Sukato DC          Journal of Vascular and Interventional Radiology (2015)        Full-text             Retrospective                PA, US                         2000.8-- 2012.11          Intermediate- or advanced-stage HCC patients treated with radioembolization                    176
  Sullivan KM        Journal of Surgical Oncology (2014)                            Full-text             NA                           WI, US                         2011.7-- 2012.4           HCC patients                                                                                   75
  Sun Q              Biomedical Research (2014)                                     Full-text             Retrospective                Beijing, China                 2003-- 2008               HCC patients treated with resection                                                            80
  Tajiri K           Journal of Gastroenterology and Hepatology (2016)              Full-text             Retrospective                Toyama, Japan                  2003-- 2014               HCC patients treated with RFA                                                                  163
  Tajiri K           Hepatology Research (2015)                                     Full-text             Retrospective                Toyama, Japan                  2010-- 2013               Advanced HCC patients treated with hepatic arterial infusion chemotherapy                      26
  Terashima T        Hepatology Research (2015)                                     Full-text             Retrospective                Ishikawa, Japan                2003.3-- 2012.12          Advanced HCC patients treated with hepatic arterial infusion chemotherapy                      266
  Uchida K           American Journal of Transplantation (2012)                     Abstract              NA                           FL, US                         2002.3-- 2010.12          HCC patients treated with DDLT                                                                 275
  Wang GY            PLoS ONE (2011)                                                Full-text             Retrospective                Guangzhou, China               2003.10-- 2009.6          HBV-associated HCC patients treated with LT                                                    101
  Wang K             Liver Transplantation (2013)                                   Abstract              Retrospective                Hangzhou, China                NA                        HCC patients treated with LT                                                                   235
  Wang Q             Annals of Surgical Oncology (2015)                             Full-text             NA                           NY, US                         1983-- 2013               HBV-associated HCC patients treated with resection                                             234
  Wang W             Hepatology Research (2015)                                     Full-text             Retrospective                Hangzhou, China                2002.1-- 2012.12          Male HCC patients treated with LT                                                              248
  Wei K              Medical Oncology (2014)                                        Full-text             Retrospective                Tianjin, China                 2010.1.1-- 2013.5.31      Intermediate-advanced HCC patients treated with concurrent TAE in combination with sorafenib   40
  Weinmann AJ        Hepatology (2015)                                              Abstract              Retrospective                Mainz, Germany                 2007-- 2013               HCC patients treated with sorafenib                                                            148
  Xiao GQ            Hepatobiliary and Pancreatic Diseases International (2015);    Full-text             Retrospective                Chengdu, China                 1999.2-- 2012.9           HCC patients treated with LT                                                                   305
  Xu X               Chinese Medical Journal (2014)                                 Full-text             Retrospective                Xi\'an, China                  2003.7-- 2012.9           HCC patients treated with TACE                                                                 178
  Xue TC             Tumor Biology (2015)                                           Full-text             Retrospective                Shanghai, China                2008.1-- 2011.3           Huge HCC patients treated with TACE                                                            165
  Yamamura K         Journal of Hepato-Biliary-Pancreatic Sciences (2014)           Full-text             Prospective                  Aichi, Japan                   2003.1-- 2012.12          HCC patients treated with resection                                                            113
  Yang X             Chinese Journal of Radiology (2015)                            Full-text             Retrospective                Chengdu, China                 2000-- 2010               HBV-associated HCC patients treated with TACE                                                  546
  Yang Z             Oncotarget (2015)                                              Full-text             Retrospective                Shanghai, China                2009.9-- 2015.5           HBV-associated HCC patients treated with TACE                                                  189
  Yip V              HPB (2011)                                                     Abstract              NA                           Liverpool, UK                  1997-- 2008               HCC patients treated with resection                                                            47
  Yoshizumi T        Anticancer Research (2016)                                     Full-text             NA                           Fukuoka, Japan                 1999.4-- 2015.3           HCC patients within Milan criteria treated with LDLT                                           129
  Yoshizumi T        Transplantation Proceedings (2013)                             Full-text             NA                           Fukuoka, Japan                 1999.4-- 2011.12          HCC patients within Kyushu University criteria treated with LDLT                               152
  Yoshizumi T        Hepatology Research (2013)                                     Full-text             NA                           Fukuoka, Japan                 1999.4-- 2012.8           Recurrent HCC adult patients treated with LDLT                                                 104
  Young AL           Journal of American College of Surgeons (2012)                 Full-text             Retrospective                Leeds, UK                      1994.1.1-- 2008.12.31     HCC patients treated with resecction                                                           142
  Zhang J            Oncology Letters (2014)                                        Full-text             Retrospective                Wuhan, China                   2002.3-- 2012.8           Non-viral HCC patients treated with TACE                                                       138
  Zhang W            Medical Oncology (2015)                                        Full-text             Retrospective                Tianjin, China                 2009.8.1-- 2012.3.28      HCC patients who received sorafenib after resection                                            38
  Zheng YB           Asian Pacific Journal of Cancer Prevention (2013)              Full-text             Retrospective                Guangzhou, China               2011.1-- 2012.12          HCC patients treated with sorafenib monotherapy                                                65
  Zheng YB           Chinese Journal of Interventional Imaging and Therapy (2013)   Full-text             Retrospective                Guangzhou, China               2008.1-- 2012.12          HCC patients treated with TACE                                                                 77
  Zhou D             Scientific Reports (2015)                                      Full-text             Retrospective                Guangzhou, China               2007-- 2009               HCC patients treated with surgical resection, ablative therapy, and TACE                       1061
  Zhou DS            World Journal of Gastroenterology (2015)                       Full-text             Retrospective                Guangzhou, China               2009.9-- 2011.11          HBV--related HCC patients treated with TACE                                                    224

Abbreviations: DDLT, deceased donor liver transplantation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; LDLT, living donor liver transplantation; LT, liver transplantation; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.

Notes:

Some data from Kinoshita A, Annals of Surgical Oncology (2015) is also published by the same authors in British Journal of Cancer (2012).

Some data from Wang GY, PLoS ONE (2011) is also published by the same authors in National Medical Journal of China (2011).

Some data from Xiao GQ, Hepatobiliary and Pancreatic Diseases International (2015) is also published by the same authors in World Journal of Gastroenterology (2013) and Hepato-gastroenterology (2014).

Study quality {#s2_2}
-------------

Quality of included studies was summarized in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. Three, 18, 12, 30, and 27 studies had 7, 6, 5, 4, and ≤ 3 points, respectively.

Meta analyses {#s2_3}
-------------

Association of baseline NLR with overall survival {#s2_4}
-------------------------------------------------

There were 39 groups of individual data regarding the association of baseline NLR with overall survival. They were extracted from 38 papers. HR was 1.80 (95% CI: 1.59--2.04, *p* \< 0.00001), suggesting that low baseline NLR group had a significantly better overall survival than high baseline NLR group (Figure [2](#F2){ref-type="fig"}). Heterogeneity among studies was statistically significant (*I*^2^ = 86%, *p* \< 0.00001). Funnel plot suggested a potential publication bias ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

![Forest plot evaluating the association between baseline NLR and overall survival in HCC patients](oncotarget-07-45283-g002){#F2}

Association of post-treatment NLR with overall survival {#s2_5}
-------------------------------------------------------

There were 4 groups of individual data regarding the association of post-treatment NLR with overall survival. They were extracted from 3 papers. HR was 1.90 (95% CI: 1.22--2.94, *p* = 0.004), suggesting that low post-treatment NLR group had a significantly better overall survival than high post-treatment NLR group (Figure [3](#F3){ref-type="fig"}). Heterogeneity among studies was statistically significant (*I*^2^ = 89%, *p* \< 0.00001).

![Forest plot evaluating the association between post-treatment NLR and overall survival in HCC patients](oncotarget-07-45283-g003){#F3}

Association of NLR change with overall survival {#s2_6}
-----------------------------------------------

There were 7 groups of individual data regarding the association of NLR change with overall survival. They were extracted from 7 papers. HR was 2.23 (95% CI: 1.83--2.72, *p* \< 0.00001), suggesting that decreased NLR group had a significantly better overall survival than increased NLR group (Figure [4](#F4){ref-type="fig"}). Heterogeneity among studies was not statistically significant (*I*^2^ = 0%, *p* = 0.95).

![Forest plot evaluating the association between NLR change and overall survival in HCC patients](oncotarget-07-45283-g004){#F4}

Association of baseline NLR with recurrence-free or disease-free survival {#s2_7}
-------------------------------------------------------------------------

There were 20 groups of individual data regarding the association of baseline NLR with recurrence-free or disease-free survival. They were extracted from 20 papers. HR was 2.23 (95% CI: 1.80--2.76, *p* \< 0.00001), suggesting that low baseline NLR group had a significantly better recurrence-free or disease-free survival than high baseline NLR group (Figure [5](#F5){ref-type="fig"}). Heterogeneity among studies was statistically significant (*I*^2^ = 88%, *p* \< 0.00001). Funnel plot suggested a potential publication bias ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}).

![Forest plot evaluating the association between baseline NLR and recurrence-free or disease-free survival in HCC patients](oncotarget-07-45283-g005){#F5}

Association of NLR change with recurrence-free or disease-free survival {#s2_8}
-----------------------------------------------------------------------

There were 4 groups of individual data regarding the association of NLR change with recurrence-free or disease-free survival. They were extracted from 4 papers. HR was 2.23 (95% CI: 1.83--2.72, *p* \< 0.00001), suggesting that decreased NLR group had a significantly better overall survival than increased NLR group (Figure [6](#F6){ref-type="fig"}). Heterogeneity among studies was not statistically significant (*I*^2^ = 0%, *p* = 0.52).

![Forest plot evaluating the association between NLR change and recurrence-free or disease-free survival in HCC patients](oncotarget-07-45283-g006){#F6}

Subgroup meta-analyses {#s2_9}
----------------------

Results of subgroup meta-analyses were summarized in Table [2](#T2){ref-type="table"}.

###### Results of subgroup meta-analyses

  Items                                                           No. groups of data   No. Pts in High NLR group   No. Pts in Low NLR group   Hazard ratio (95% CI)   *P* value    Heterogeneity   
  --------------------------------------------------------------- -------------------- --------------------------- -------------------------- ----------------------- ------------ --------------- ------------
  **Overall survival & baseline NLR**                                                                                                                                                              
  ***Subgroup analysis according to treatment option***                                                                                                                                            
   Liver transplantation                                          7                    330                         740                        2.38 (1.95--2.91)       \< 0.00001   38%             0.14
   Surgical resection                                             12                   914                         2183                       1.95 (1.61--2.37)       \< 0.00001   62%             0.002
   Radiofrequency ablation                                        1                    68                          110                        0.94 (0.64--1.39)       0.76         NA              NA
   Transarterial chemoembolization                                9                    653                         1045                       1.29 (1.20--1.38)       \< 0.00001   14%             0.32
   Radioembolization                                              1                    48                          128                        1.38 (1.09--1.74)       0.008        NA              NA
   Hepatic arterial infusion chemotherapy                         2                    141                         151                        1.28 (1.07--1.52)       0.006        0%              0.43
   Transarterial embolization + sorafenib                         1                    19                          21                         2.34 (1.25--4.38)       0.008        NA              NA
   Sorafenib                                                      2                    102                         68                         1.49 (1.17--1.91)       0.001        0%              0.73
   Mixed                                                          4                    933                         1476                       2.59 (1.68--4.00)       \< 0.0001    94%             \< 0.00001
  ***Subgroup analysis according to NLR cut-off value range***                                                                                                                                     
   NLR cut-off value ≥ 1, \< 2                                    2                    110                         246                        1.22 (0.77--1.93)       0.4          73%             0.05
   NLR cut-off value ≥ 2, \< 3                                    16                   2077                        3289                       1.93 (1.56--2.39)       \< 0.00001   91%             \< 0.00001
   NLR cut-off value ≥ 3, \< 4                                    7                    515                         903                        1.55 (1.28--1.88)       \< 0.00001   75%             0.0005
   NLR cut-off value = 4                                          6                    308                         349                        2.07 (1.73--2.49)       \< 0.00001   0%              0.63
   NLR cut-off value = 5                                          8                    198                         1135                       1.86 (1.37--2.52)       \< 0.0001    83%             \< 0.00001
  ***Subgroup analysis according to regions***                                                                                                                                                     
   America                                                        8                    251                         680                        1.55 (1.30--1.84)       \< 0.00001   26%             0.22
   Asia                                                           30                   2934                        5095                       1.81 (1.57--2.08)       \< 0.00001   88%             \< 0.00001
   Europe                                                         1                    23                          147                        3.9 (2.63--5.77)        \< 0.00001   NA              NA
  **Overall survival & post-treatment NLR**                                                                                                                                                        
  ***Subgroup analysis according to treatment option***                                                                                                                                            
   Transarterial chemoembolization                                1                    18                          59                         2.03 (1.35--3.07)       0.0007       NA              NA
   Hepatic arterial infusion chemotherapy                         2                    62                          181                        1.5 (0.92--2.43)        0.1          76%             0.04
   Mixed                                                          1                    273                         473                        2.69 (2.17--3.34)       \< 0.00001   NA              NA
  ***Subgroup analysis according to NLR cut-off value range***                                                                                                                                     
   NLR cut-off value ≥ 2, \< 3                                    3                    335                         654                        1.86 (1.06--3.26)       0.03         92%             \< 0.00001
   NLR cut-off value = 4                                          1                    18                          59                         2.03 (1.35--3.07)       0.0007       NA              NA
  ***Subgroup analysis according to regions***                                                                                                                                                     
   Asia                                                           4                    353                         713                        1.9 (1.22--2.94)        0.004        89%             \< 0.00001
  **Overall survival & NLR change**                                                                                                                                                                
  ***Subgroup analysis according to treatment option***                                                                                                                                            
   Surgical resection                                             2                    220                         166                        2.06 (1.37--3.11)       0.0006       0%              0.68
   Radiofrequency ablation                                        1                    91                          87                         2.2 (1.49--3.26)        \< 0.00001   NA              NA
   Microwave ablation                                             1                    44                          16                         1.99 (1.06--3.73)       0.03         NA              NA
   Transarterial chemoembolization                                2                    156                         36                         2.12 (1.39--3.24)       0.0005       0%              0.86
   Sorafenib                                                      1                    13                          25                         2.86 (1.79--4.57)       \< 0.00001   NA              NA
  ***Subgroup analysis according to NLR cut-off value change***                                                                                                                                    
   Increase or decrease                                           6                    384                         273                        2.26 (1.84--2.78)       \< 0.00001   0%              0.94
   Delta                                                          1                    140                         57                         1.77 (0.76--4.11)       0.18         NA              NA
  ***Subgroup analysis according to regions***                                                                                                                                                     
   Asia                                                           6                    495                         321                        2.23 (1.81--2.74)       \< 0.00001   0%              0.9
   Europe                                                         1                    29                          9                          2.27 (0.98--5.27)       0.06         NA              NA
  **RFS/DFS & baseline NLR**                                                                                                                                                                       
  ***Subgroup analysis according to treatment option***                                                                                                                                            
   Liver transplantation                                          9                    460                         1088                       3.31 (2.05--5.32)       \< 0.00001   89%             \< 0.00001
   Surgical resection                                             8                    536                         1147                       1.87 (1.47--2.37)       \< 0.00001   76%             0.0002
   Radiofrequency ablation                                        1                    68                          110                        1.01 (0.77--1.33)       0.94         NA              NA
   Thermal ablation                                               1                    183                         323                        2.64 (2.26--3.09)       \< 0.00001   NA              NA
   Transarterial chemoembolization                                1                    42                          136                        1.38 (1.07--1.78)       0.01         NA              NA
  ***Subgroup analysis according to NLR cut-off value range***                                                                                                                                     
   NLR cut-off value ≥ 1, \< 2                                    2                    110                         246                        1.18 (0.87--1.6)        0.27         62%             0.1
   NLR cut-off value ≥ 2, \< 3                                    6                    655                         958                        1.9 (1.4--2.59)         \< 0.0001    90%             \< 0.00001
   NLR cut-off value ≥ 3, \< 4                                    3                    158                         304                        1.72 (1.17--2.54)       0.006        73%             0.03
   NLR cut-off value = 4                                          4                    266                         453                        2.75 (1.63--4.63)       0.001        62%             0.05
   NLR cut-off value = 5                                          5                    100                         843                        4.51 (2.24--9.12)       \< 0.0001    85%             \< 0.0001
  ***Subgroup analysis according to regions***                                                                                                                                                     
   America                                                        2                    41                          269                        6.07 (1.34--27.55)      0.02         87%             0.006
   Asia                                                           16                   1199                        2318                       1.85 (1.53--2.24)       \< 0.00001   83%             \< 0.00001
   Europe                                                         2                    49                          217                        4.77 (1.04--21.77)      0.04         94%             \< 0.0001
  **RFS/DFS & NLR change**                                                                                                                                                                         
  ***Subgroup analysis according to treatment option***                                                                                                                                            
   Surgical resection                                             2                    220                         166                        1.82 (1.42--2.34)       \< 0.00001   0%              0.4
   Radiofrequency ablation                                        1                    91                          87                         1.55 (1.20--2.00)       0.007        NA              NA
   Sorafenib                                                      1                    13                          25                         2.05 (1.39--3.04)       0.0003       NA              NA
  ***Subgroup analysis according to NLR cut-off value change***                                                                                                                                    
   Increase or decrease                                           3                    184                         221                        1.77 (1.48--2.12)       \< 0.00001   2%              0.36
   Delta                                                          1                    140                         57                         1.58 (1.05--2.39)       0.03         NA              NA
  ***Subgroup analysis according to regions***                                                                                                                                                     
   Asia                                                           4                    324                         278                        1.74 (1.48--2.05)       \< 0.00001   0%              0.52

DISCUSSION {#s3}
==========

The present study systematically reviewed the role of NLR in the assessment of prognosis of HCC patients. To our knowledge, two previous meta-analyses also explored the association of NLR with prognosis of HCC \[[@R102]--[@R103]\]. Both of them were published in 2014. In the first meta-analysis, Xiao et al. searched the relevant literatures in August 2013 and identified 15 studies with 3,094 patients \[[@R102]\]. In the second meta-analysis, Xue et al. searched the relevant literatures in October 2013 and identified 26 studies with 4,461 patients \[[@R103]\]. Several advantages and features of our work should be acknowledged: 1) the relevant literatures were identified more recently (January 2016), and a larger number of relevant studies were included (90 papers with 20,475 patients); 2) according to the different time points when NLR values were obtained, we divided into baseline NLR, post-treatment NLR, and NLR change; 3) overall survival and recurrence-free or disease-free survival were selected as the primary outcomes; and 4) according to the treatment options, NLR cut-off values, and regions, we performed subgroup meta-analyses.

The major finding of our study was that low baseline NLR was significantly associated with better overall survival and recurrence-free or disease-free survival of HCC patients. This was based on a relatively large number of relevant data (38 papers for overall survival and 20 papers for recurrence-free or disease-free survival). Therefore, in our opinion, the relationship of baseline NLR with survival of HCC patients should be stable. This consideration was also confirmed by the subgroup meta-analyses: 1) except for one subgroup meta-analysis in patients undergoing radiofrequency ablation, other subgroup meta-analyses in patients undergoing different treatment modalities supported such an inverse association between them; 2) except for one subgroup meta-analysis with a NLR cut-off value of ≥ 1 and \< 2, other subgroup meta-analyses with other NLR cut-off value ranges supported such an inverse association between them; and 3) regardless of regions, subgroup meta-analyses supported such an inverse association between them. Certainly, two following issues should be acknowledged. First, only one study focused on the patients undergoing radiofrequency ablation. Thus, more data might be necessary for the validation of our findings. Second, only two studies employed a NLR cut-off value of ≥ 1 and \< 2. Given such a small NLR cut-off value, the survival difference between high and low NLR groups might be hardly achieved.

Another finding was that low post-treatment NLR was significantly associated with better overall survival of HCC patients. However, due to a small number of included studies, the subgroup meta-analyses were performed in patients undergoing transarterial chemoembolization and hepatic arterial infusion chemotherapy, studies with a NLR cut-off value of ≥ 2 and \< 3 and NLR cut-off value of 4, and Asian studies. Except for one subgroup meta-analysis in HCC patients undergoing hepatic arterial infusion chemotherapy, other subgroup meta-analyses supported statistically significant associations. Similarly, we also found that decreased NLR after treatment was significantly associated with better recurrence-free or disease-free survival of HCC patients. Notably, such an inverse association was maintained regardless of treatment modalities.

Several limitations should be clarified. First, HR value for the association of NLR with overall survival was relatively small. Thus, their relationship might be weak. Whether the prognostic assessment of HCC can be guided by baseline NLR value should be further explored. Second, all included studies were observational, and most of them were retrospective. The quality of included studies was relatively low according to the NEWCASTLE-OTTAWA quality assessment scale. A major concern was a low comparability of patient characteristics between low and high NLR groups. This was primarily because all included studies were observational and NLR was only one of many variables included in univariate or multivariate analyses in a majority of original studies. Third, the heterogeneity was statistically significant in several meta-analyses. Random-effect model was employed to produce more conservative results. Fourth, because the researchers paid close attention on the prognostic role of NLR, some relevant paper has been published after this paper was finished \[[@R104]\].

In conclusion, the importance of NLR for assessing the overall survival and recurrence-free or disease-free survival should be acknowledged. Thus, we would like to suggest that NLR may be incorporated into the algorithm regarding the prognostic assessment of HCC. Further studies should confirm the prognostic ability of NLR in different specific settings according to the stage of HCC and treatment options and explore the superiority of NLR over other traditional prognostic scores or models. Additionally, considering that NLR change was associated with prognosis of HCC patients, future studies should explore how to prolong the survival of HCC patients by improving the inflammatory conditions.

MATERIALS AND METHODS {#s4}
=====================

We searched 3 major databases, including PubMed, EMBASE, and Cochrane library databases from the inception of databases. Search items were as follows: ((hepatocellular carcinoma) OR (liver cancer)) AND ((NLR) OR ((neutrophil) AND lymphocyte)). The last search was performed on January 20, 2016. All relevant literatures regarding the prognostic role of NLR in HCC patients were identified. Exclusion criteria were as follows: 1) duplicates; 2) comments; 3) erratum; 4) reviews; 5) case reports; 6) experimental studies; and 7) original studies did not evaluate the prognostic role of NLR in HCC patients. Publication language was not restricted.

We extracted the following data from the included studies: first author, journal, publication year, publication type, study design, regions, enrollment period, study population, number of patients, NLR cut-off values, and overall survival and recurrence-free or disease-free survival data according to the NLR value. In cases of uncertainty, we communicated with the authors and/or journal editors to validate the accuracy of data.

Given the nature of included studies, the study quality was assessed according to the NEWCASTLE-OTTAWA quality assessment scale for cohort studies \[[@R105]\]. This scale consisted of 8 questions with a maximum of 9 points. A study with more points would be of higher quality.

Data analysis was described as previously \[[@R106]--[@R108]\]. Briefly, only random-effects models were employed. Hazard ratios (HRs) were calculated because the overall survival and recurrence-free or disease-free survival were time-dependent data. I^2^ statistic and the Chi-square test were used to evaluate the heterogeneity among studies. Funnel plots were performed to evaluate the publication bias, if there were ≥ 10 groups of individual data included in the meta-analysis.

Notably, the meta-analyses were performed according to the times when NLR values were obtained (i.e. baseline NLR, post-treatment NLR, and NLR change). As for the baseline and post-treatment NLR, the patients were divided into two groups (i.e., low and high NLR group) according to the definitions of original studies. If the patients were divided into ≥ 3 groups in the original studies, the relevant data would not be included in the meta-analyses. Additionally, subgroup meta-analyses were performed according to the treatment options (i.e., liver transplantation, surgical resection, radiofrequency ablation, transarterial chemoembolization, radioembolization, hepatic arterial infusion chemotherapy, transarterial embolization plus sorafenib, sorafenib, and mixed treatments), NLR cut-off value ranges, and regions (i.e., America, Asia, and Europe).

SUPPLEMENTARY MATERIALS FIGURES AND TABLE {#s5}
=========================================
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